FOXP3 and breast cancer: Among clinical trials Dr. Sylvain Ladoire performed clinical trial (ClinicalTrials.gov Identifier: NCT01513408) at Centre Georges Francois Leclerc with 500 participants with a topic, “Prospective study of the relevance of T lymphocytes tumor infiltrates D8 and FOXP3 as a new immune prognostic biomarker in breast cancer treated by neoadjuvant chemotherapy to verify that accumulation of regulatory T-lymphocytes expressing FOXP3 is associated with poor prognosis in breast cancer patients.